Last reviewed · How we verify
ARGX-113 with rHuPH20
Monoclonal antibody targeting the neonatal Fc receptor (FcRn)
Monoclonal antibody targeting the neonatal Fc receptor (FcRn) Used for Primary immunodeficiency.
At a glance
| Generic name | ARGX-113 with rHuPH20 |
|---|---|
| Also known as | efgartigimod with rHuPH20 |
| Sponsor | argenx |
| Drug class | Monoclonal antibody |
| Target | FcRn |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 1 |
Mechanism of action
ARGX-113 with rHuPH20 is a monoclonal antibody that targets the neonatal Fc receptor (FcRn) to reduce the levels of immunoglobulin G (IgG) in the body.
Approved indications
- Primary immunodeficiency
Common side effects
Key clinical trials
- A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid (PHASE3)
- A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) (PHASE3)
- Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARGX-113 with rHuPH20 CI brief — competitive landscape report
- ARGX-113 with rHuPH20 updates RSS · CI watch RSS
- argenx portfolio CI